Upadacitinib for moderate-to-severe atopic dermatitis: stratified analysis from three randomized phase 3 trials by key baseline characteristics.
Jacob Pontoppidan ThyssenD ThaçiT BieberMelinda J GooderhamM de Bruin-WellerW SoongK KabashimaSébastien BarbarotP C LunaJ XuX HuY LiuE M RaymundoBrian M CalimlimC NduakaA GamelliEric L SimpsonPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
ClinicalTrials.gov Identifiers: NCT03569293 (Measure Up 1), NCT03607422 (Measure Up 2), and NCT03568318 (AD Up).